Phase 3 readouts expected in 2030

Every Phase 3 and Phase 2/3 study on a drug AssetMemo covers whose estimated primary completion date falls in 2030, by month. The primary completion date is the sponsor's estimate of when the last participant is assessed for the primary endpoint, so it is the nearest public marker of a readout, not a confirmed date. Dates move: recent moves are on the delayed readouts page, and every phase is on the readout calendar.

Summary

266 studies (222 Phase 3, 44 Phase 2/3) across 218 drugs.

January 2030

Primary completionDrugDeveloperIndicationPhaseStudy
2030-01 (month only)TricaprilinCerecin (Singapore, formerly Accera, Nestle Health Science-backed)Alzheimer's DiseasePhase 3NCT05809908
2030-01 (month only)AficamtenBayer, Cytokinetics, SanofiHypertrophic CardiomyopathyPhase 2/3NCT06412666
2030-01 (month only)Nivolumab, Ipilimumab, Sturlimogene erparepvecBristol-Myers Squibb, Ono Pharmaceutical, Replimune, Inc.Melanoma, Uveal MelanomaPhase 2/3NCT06581406
2030-01 (month only)AtezolizumabChugai Pharma, RocheSmall Cell Lung CancerPhase 3NCT07625644
2030-01 (month only)TislelizumabBeOne MedicinesIntrahepatic Cholangiocarcinoma (Icc)Phase 3NCT07691515
2030-01-01DurvalumabAstraZenecaEndometrial CancerPhase 3NCT05255653
2030-01-01Naloxone (Narcan)Emergent BioSolutionsOpioid Use DisorderPhase 3NCT06089707
2030-01-01fingolimod (Gilenya), UblituximabNovartis, Tanabe Pharma Corporation, NeuraxpharmMultiple SclerosisPhase 2/3NCT07220252
2030-01-01TicagrelorAstraZenecaNSTEMI - Non-ST Segment Elevation MI, STEMI (ST Elevation MI), Myocardial InfarctionPhase 3NCT07257198
2030-01-01Tafolecimab, Sintilimab, CapecitabineInnovent Biologics, Cheplapharm Arzneimittel GmbHLocal Advanced Rectal Cancer, PD-1 Inhibitor, PCSK9 Inhibitor, RCT, Radiotherapy, Capecitabine, OxaliplatinPhase 3NCT07686796
2030-01-08SotaterceptMerck & Co.Heart FailurePhase 3NCT07839585
2030-01-09PelacarsenIonis Pharmaceuticals, NovartisAtherosclerotic Cardiovascular DiseasePhase 3NCT07517263
2030-01-14Venglustat (GZ/SAR402671)SanofiGaucher DiseasePhase 3NCT07927140
2030-01-15Pimurutamab, HLX43Shanghai Henlius BiotechNon-Small Cell Lung CancerPhase 2/3NCT07459751
2030-01-16Cemiplimab, Fianlimab, pemetrexedRegeneron Pharmaceuticals, Eli LillyNon-Small Cell Lung CancerPhase 2/3NCT05800015
2030-01-17RilvegostomigAstraZeneca, COMPUGEN LTDNon-Small Cell Lung CancerPhase 3NCT06868277
2030-01-18Pozelimab, CemdisiranRegeneron Pharmaceuticals, Alnylam PharmaceuticalsParoxysmal Nocturnal HemoglobinuriaPhase 3NCT07154745
2030-01-23CenvacibartRegeneron PharmaceuticalsCancer-Associated Thrombosis (CAT)Phase 3NCT07410117
2030-01-24Nab-paclitaxel, SCTB41, pemetrexedBristol-Myers Squibb, Sinocelltech Group Ltd., Eli LillyNon-Small Cell Lung CancerPhase 2/3NCT07662395
2030-01-28FelzartamabBiogenPrimary Membranous NephropathyPhase 3NCT06962800
2030-01-30CapecitabineCheplapharm Arzneimittel GmbHRectal CancerPhase 3NCT06205485
2030-01-31NivolumabBristol-Myers Squibb, Ono PharmaceuticalClinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Phase 3NCT03811015
2030-01-31Pembrolizumab, pemetrexedMerck & Co., Eli LillyNon-Small Cell Lung CancerPhase 3NCT04267848
2030-01-31vedolizumabTakeda Pharmaceutical CompanyPouchitisPhase 3NCT06443502
2030-01-31VenetoclaxAbbVie, RocheAcute Myeloid LeukemiaPhase 3NCT07396480
2030-01-31TislelizumabBeOne MedicinesHCC - Hepatocellular CarcinomaPhase 3NCT07475026

February 2030

Primary completionDrugDeveloperIndicationPhaseStudy
2030-02 (month only)autologous cultured chondrocytes on porcine collagen membraneVericel CorporationChondral Defect, Osteochondritis Dissecans (OCD), Articular Cartilage Defect, Articular Cartilage Disorder of KneePhase 3NCT03588975
2030-02 (month only)sildenafilPfizer, ViatrisRectal CancerPhase 3NCT06123156
2030-02-02Pumitamig, BevacizumabBioNTech, Bristol-Myers Squibb, RocheColorectal Cancer, Metastatic Colorectal CancerPhase 2/3NCT07221357
2030-02-07apremilastAmgenBehçet DiseasePhase 3NCT04528082
2030-02-10RibociclibNovartisBreast CancerPhase 3NCT07400523
2030-02-18DeulumateperoneIntra-Cellular Therapies, Johnson & JohnsonGeneralized Anxiety DisorderPhase 3NCT07807865
2030-02-20Toripalimab, CapecitabineCoherus BioSciences, Inc., Shanghai Junshi Bioscience, Cheplapharm Arzneimittel GmbHNasopharyngeal CarcinomaPhase 3NCT06277050
2030-02-21Sodium zirconium cyclosilicateAstraZenecaHyperkalaemiaPhase 3NCT03813407
2030-02-21BuntanetapAnnovis Bio (NYSE American: ANVS)Alzheimer's Dementia (AD)Phase 2/3NCT07757204
2030-02-23PF-08634404Pfizer, Shenyang Sunshine PharmaceuticalColorectal CancerPhase 3NCT07222800
2030-02-26Rimegepant (Nurtec ODT)Eisai, PfizerMigrainePhase 3NCT06616194
2030-02-26Trastuzumab DeruxtecanAstraZeneca, Daiichi SankyoEndometrial CancerPhase 3NCT07022483
2030-02-26Nerandomilast (Jascayd)Boehringer IngelheimSystemic SclerosisPhase 3NCT07497087
2030-02-28BevacizumabRocheOvarian CancerPhase 3NCT07779538

March 2030

Primary completionDrugDeveloperIndicationPhaseStudy
2030-03 (month only)Ibrutinib, RituximabAbbVie, Johnson & Johnson, BiogenWaldenstrom MacroglobulinemiaPhase 2/3NCT04061512
2030-03 (month only)Semaglutide (Ozempic)Novo NordiskGlucose Intolerance After a Recent History of Gestational DiabetesPhase 3NCT05569772
2030-03 (month only)Tamoxifen (Soltamox), Anastrozole, Letrozole, ExemestaneMayne Pharma, Rosemont Pharmaceuticals, ANI Pharmaceuticals, Inc.HR+/HER2- Metastatic Breast Cancer, Breast CancerPhase 3NCT05645536
2030-03 (month only)LorlatinibPfizerNon-Small Cell Lung CancerPhase 3NCT06858410
2030-03 (month only)CapivasertibAstex Pharmaceuticals, Inc., AstraZenecaHR+/HER2- Metastatic Breast Cancer, Breast CancerPhase 3NCT07281833
2030-03 (month only)N-acetylcysteineApotex Inc., Phebra Pty LtdMild DepressionPhase 3NCT07464886
2030-03 (month only)AlirocumabRegeneron Pharmaceuticals, SanofiCarotid StenosisPhase 3NCT07586540
2030-03 (month only)orforglipronChugai Pharma, Eli LillyType 2 DiabetesPhase 3NCT07668336
2030-03 (month only)Telisotuzumab AdizutecanAbbVieNon-Small Cell Lung CancerPhase 3NCT07821684
2030-03 (month only)Rinatabart sesutecan (Rina-S)GenmabOvarian CancerPhase 3NCT07859215
2030-03-01AvacopanAmgen, Vifor PharmaANCA-Associated Vasculitis (AAV)Phase 3NCT07373262
2030-03-01Bevacizumab, CapecitabineRoche, Cheplapharm Arzneimittel GmbHHepatocellular CarcinomaPhase 2/3NCT07392866
2030-03-04Pembrolizumab, Datopotamab DeruxtecanMerck & Co., AstraZeneca, Daiichi SankyoNon-Small Cell Lung CancerPhase 3NCT05215340
2030-03-04Abemaciclib, CamizestrantEli Lilly, AstraZenecaBreast CancerPhase 3NCT05952557
2030-03-06deucravacitinibBristol-Myers SquibbPsoriatic ArthritisPhase 3NCT06869551
2030-03-08vedolizumabTakeda Pharmaceutical CompanyCrohn's DiseasePhase 3NCT05837897
2030-03-08Xanomeline/trospium chlorideBristol-Myers Squibb, Zai LabSchizophreniaPhase 3NCT07424404
2030-03-13DostarlimabGlaxoSmithKlineRectal CancerPhase 3NCT07740720
2030-03-15Rilvegostomig, Bevacizumab, TremelimumabAstraZeneca, COMPUGEN LTD, RocheHepatocellular CarcinomaPhase 3NCT06921785
2030-03-20cagrilintide, Semaglutide (Wegovy)Novo NordiskObesityPhase 3NCT07253285
2030-03-21Nerandomilast (Jascayd)Boehringer IngelheimIdiopathic Inflammatory MyopathiesPhase 3NCT07789015
2030-03-25SintilimabInnovent BiologicsLocally Advanced Rectal CancerPhase 3NCT07917468
2030-03-30Sacituzumab TirumotecanMerck & Co., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Breast CancerPhase 3NCT07628504
2030-03-31VenetoclaxAbbVie, RocheAcute Myeloid LeukemiaPhase 2/3NCT06972641
2030-03-31afimkibartPfizer, RocheUlcerative ColitisPhase 3NCT07158242
2030-03-31Anakinra, tocilizumabSwedish Orphan Biovitrum AB (publ), Chugai Pharma, RocheNew Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)Phase 3NCT07281027
2030-03-31DocetaxelSanofiProstate CancerPhase 3NCT07333066
2030-03-31Pembrolizumab, Enfortumab VedotinMerck & Co., Astellas Pharma, PfizerUrothelial Carcinoma, Bladder CancerPhase 3NCT07566156

April 2030

Primary completionDrugDeveloperIndicationPhaseStudy
2030-04 (month only)PyrotinibDr. Reddy's Laboratories, HLB Life Science, Jiangsu Hengrui PharmaceuticalsHER2-Positive Breast CancerPhase 3NCT05910398
2030-04 (month only)upadacitinibAbbVieAlopecia AreataPhase 3NCT06012240
2030-04 (month only)Trastuzumab rezetecanGlenmark Pharmaceuticals Ltd., Jiangsu Hengrui PharmaceuticalsBreast CancerPhase 3NCT06126640
2030-04 (month only)HRS-1780Jiangsu Hengrui PharmaceuticalsChronic Kidney DiseasePhase 3NCT07419828
2030-04 (month only)Venetoclax, Azacitidine, QuizartinibAbbVie, Roche, Bristol-Myers SquibbAcute Myeloid LeukemiaPhase 3NCT07478991
2030-04 (month only)DonanemabEli LillyAlzheimer's DiseasePhase 3NCT07571161
2030-04 (month only)AfimetoranBeeline Medicines, Bristol-Myers SquibbCutaneous Lupus Erythematosus (CLE), Systematic Lupus ErythematosusPhase 2/3NCT07881120
2030-04-01NedosiranNovo NordiskPrimary Hyperoxaluria Type 1Phase 3NCT04042402
2030-04-01NivolumabBristol-Myers Squibb, Ono PharmaceuticalNon-Small Cell Lung CancerPhase 3NCT04564157
2030-04-01BevacizumabRocheColorectal CancerPhase 3NCT05797467
2030-04-01SintilimabInnovent BiologicsNasopharyngeal Carcinoma (NPC)Phase 3NCT07459296
2030-04-01VenetoclaxAbbVie, RocheAcute Myeloid LeukemiaPhase 3NCT07539818
2030-04-02TarlatamabAmgenSmall Cell Lung CancerPhase 3NCT06211036
2030-04-02VotoplamNovartisHuntington's DiseasePhase 3NCT07326709
2030-04-05Pembrolizumab, Pembrolizumab berahyaluronidase alfa, ZanzalintinibMerck & Co., ExelixisColorectal CancerPhase 3NCT07750158
2030-04-15bimekizumabUCBPsoriasisPhase 3NCT07836283
2030-04-17VolrustomigAstraZenecaHead and Neck Squamous Cell CarcinomaPhase 3NCT06129864
2030-04-18zasocitinibTakeda Pharmaceutical CompanyPsoriatic ArthritisPhase 3NCT07871721
2030-04-20TarlatamabAmgenSmall Cell Lung CancerPhase 3NCT06117774
2030-04-22Methotrexate, DexamethasoneLymphoblastic Lymphoma, ChildhoodPhase 3NCT04043494
2030-04-24Pembrolizumab, Trastuzumab DeruxtecanMerck & Co., AstraZeneca, Daiichi SankyoNon-Small Cell Lung CancerPhase 3NCT06899126
2030-04-30ImlifidaseHansa BiopharmaLong Term Efficacy and SafetyPhase 3NCT05937750
2030-04-30ModafinilApotex Inc.Cognition, Healthy ParticipantsPhase 3NCT07231497
2030-04-30ModafinilApotex Inc.Psychosis, Schizophrenia Disorder, Schizoaffective Disorder, Major Depressive Disorder With Psychotic Features, Bipolar Disorder With Psychotic Features, Psychosis NOS, Schizophreniform Disorder, Psychotic Disorder, CognitionPhase 3NCT07263022
2030-04-30Futibatinib (Lytgobi)Taiho PharmaceuticalBiliary Tract CancerPhase 3NCT07710885
2030-04-30RC148AbbVie, RemeGen Co., Ltd.Advanced Gastric or Gastroesophageal Junction AdenocarcinomaPhase 2/3NCT07935369

May 2030

Primary completionDrugDeveloperIndicationPhaseStudy
2030-05 (month only)Ivonescimab, LigufalimabAkeso, Summit TherapeuticsSquamous Cell Carcinoma Head and Neck Cancer (HNSCC)Phase 3NCT07264075
2030-05 (month only)Gamgertamig (CM336), LumrotatugGilead Sciences, Keymed Biosciences, Lakefront Biotherapeutics NVMultiple MyelomaPhase 3NCT07910903
2030-05-01CapecitabineCheplapharm Arzneimittel GmbHNasopharyngeal Carcinoma (NPC)Phase 3NCT06900218
2030-05-01Bevacizumab, FluzoparibRoche, Jiangsu Hengrui PharmaceuticalsOvarian CancerPhase 3NCT06954584
2030-05-03CemiplimabRegeneron PharmaceuticalsCutaneous Squamous Cell Carcinoma (CSCC)Phase 3NCT06585410
2030-05-15DapagliflozinAstraZeneca, Ono PharmaceuticalPolycystic Kidney, Autosomal DominantPhase 3NCT07280585
2030-05-18Pembrolizumab, Sacituzumab TirumotecanMerck & Co., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Breast CancerPhase 3NCT06841354
2030-05-21Bevacizumab, GSK 5733584Roche, GlaxoSmithKlineOvarian CancerPhase 3NCT07684612
2030-05-28NucresiranAlnylam PharmaceuticalsTransthyretin Amyloidosis with CardiomyopathyPhase 3NCT07052903
2030-05-29RibociclibNovartisBreast CancerPhase 3NCT03701334
2030-05-30Sintilimab, BevacizumabInnovent Biologics, RocheHepatocellular CarcinomaPhase 3NCT07594340
2030-05-31RituximabBiogen, Chugai Pharma, RocheEpstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant ComplicationsPhase 3NCT03394365
2030-05-31afimkibartPfizer, RocheCrohn's DiseasePhase 3NCT07298421
2030-05-31Atezolizumab, Nivolumab, Cabozantinib, ZanzalintinibChugai Pharma, Roche, Bristol-Myers SquibbHepatocellular Carcinoma, Colorectal Cancer, Renal Cell Carcinoma, Prostate CancerPhase 3NCT07620574
2030-05-31Adebrelimab, pemetrexedJiangsu Hengrui Pharmaceuticals, Eli LillyNon-Small Cell Lung CancerPhase 3NCT07822542

June 2030

Primary completionDrugDeveloperIndicationPhaseStudy
2030-06 (month only)LecanemabBiogen, EisaiAlzheimer's DiseasePhase 3NCT06384573
2030-06 (month only)MethylprednisolonePfizerRejectionPhase 3NCT06474273
2030-06 (month only)OlaparibAstraZeneca, Merck & Co.Endometrial Cancer, p53abnPhase 3NCT06712472
2030-06 (month only)AlixorextonAlkermes plcNarcolepsy, Idiopathic HypersomniaPhase 2/3NCT06767683
2030-06 (month only)VenetoclaxAbbVie, RocheAcute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic LymphomaPhase 2/3NCT06855810
2030-06 (month only)bleximenibJohnson & JohnsonAcute Myeloid LeukemiaPhase 3NCT07223814
2030-06 (month only)SHR-1501Jiangsu Hengrui PharmaceuticalsNMIBCPhase 3NCT07424287
2030-06 (month only)BEBT-209BeBetter MedBreast CancerPhase 2/3NCT07544056
2030-06 (month only)DR10624Zhejiang Doer BiologicsSevere HypertriglyceridemiaPhase 3NCT07680829
2030-06-01sildenafilPfizer, ViatrisCancerPhase 2/3NCT06800092
2030-06-01Trastuzumab rezetecanGlenmark Pharmaceuticals Ltd., Jiangsu Hengrui PharmaceuticalsOvarian CancerPhase 3NCT06990503
2030-06-01Donanemab, NivegacetorEli Lilly, RocheAlzheimer's DiseasePhase 2/3NCT06996730
2030-06-10SurovatamigAstraZenecaLarge B-Cell LymphomaPhase 3NCT07215585
2030-06-14PF-08634404, TarlatamabPfizer, Shenyang Sunshine Pharmaceutical, AmgenSmall Cell Lung CancerPhase 2/3NCT07226999
2030-06-15CadonilimabAkesoResectable Colon Cancer, MSI-H/dMMR Colorectal CancerPhase 3NCT07412613
2030-06-16Utidelone, CapecitabineBeijing Biostar Pharmaceuticals, Cheplapharm Arzneimittel GmbHBreast Cancer, TNBCPhase 3NCT07021261
2030-06-25Intismeran AutogeneMerck & Co., ModernaNon-Small Cell Lung CancerPhase 3NCT06077760
2030-06-26QuizartinibDaiichi Sankyo, Innovent BiologicsAcute Myeloid LeukemiaPhase 3NCT06578247
2030-06-26PF-06651600PfizerSevere Alopecia AreataPhase 3NCT07029828
2030-06-28IptacopanNovartisIgA NephropathyPhase 3NCT06994845
2030-06-28Torvutatug samrotecanAstraZenecaOvarian CancerPhase 3NCT07851025
2030-06-30Vanzacaftor / tezacaftor / deutivacaftorVertex PharmaceuticalsCystic FibrosisPhase 3NCT05422222
2030-06-30MethotrexateMature B-cell Non-Hodgkin LymphomaPhase 2/3NCT07168980
2030-06-30Thalidomide, CapecitabineBristol-Myers Squibb, Cheplapharm Arzneimittel GmbHHepatocellular CarcinomaPhase 2/3NCT07309419
2030-06-30SetidegrasibAstellas PharmaNon-Small Cell Lung CancerPhase 3NCT07566052
2030-06-30Toripalimab, Disitamab VedotinCoherus BioSciences, Inc., Shanghai Junshi Bioscience, PfizerUrinary Bladder NeoplasmsPhase 2/3NCT07608224
2030-06-30Imatinib mesylate prodrug (IkT-001Pro)Inhibikase TherapeuticsPulmonary Arterial HypertensionPhase 3NCT07632898
2030-06-30GFH375GenFleet Therapeutics, Verastem, Inc.Non-Small Cell Lung CancerPhase 3NCT07668752

July 2030

Primary completionDrugDeveloperIndicationPhaseStudy
2030-07 (month only)BelinostatAcrotech BiopharmaPeripheral T-Cell LymphomaPhase 3NCT06072131
2030-07 (month only)Bictegravir/lenacapavir (Bixlenvo)Gilead SciencesHIVPhase 2/3NCT06532656
2030-07 (month only)autologous cultured chondrocytes on porcine collagen membraneVericel CorporationChondral Defect, Articular Cartilage DefectPhase 3NCT06915233
2030-07 (month only)AvacopanAmgen, Vifor PharmaGranulomatosis With Polyangiitis, Wegener&#39Phase 2/3NCT07176546
2030-07 (month only)Obinutuzumab, LenalidomideRoche, Bristol-Myers Squibb, Celgene CorporationFollicular LymphomaPhase 3NCT07719855
2030-07-01CapecitabineCheplapharm Arzneimittel GmbHStage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Locally Advanced Rectal AdenocarcinomaPhase 2/3NCT05610163
2030-07-01Nab-paclitaxel, RilvegostomigBristol-Myers Squibb, AstraZeneca, COMPUGEN LTDNon-Small Cell Lung CancerPhase 3NCT06692738
2030-07-01Dapagliflozin, BalcinrenoneAstraZeneca, Ono PharmaceuticalChronic Kidney DiseasePhase 3NCT07624305
2030-07-04Trastuzumab Deruxtecan, Pertuzumab, PalbociclibAstraZeneca, Daiichi Sankyo, RocheHR+/HER2- Metastatic Breast Cancer, Breast CancerPhase 3NCT07683754
2030-07-08BrivaracetamUCBEpilepsyPhase 3NCT04715646
2030-07-08garetosmabRegeneron PharmaceuticalsFibrodysplasia Ossificans ProgressivaPhase 3NCT07559513
2030-07-11CliramitugAstraZenecaTransthyretin Amyloidosis with CardiomyopathyPhase 3NCT07789483
2030-07-22GSK 5733584GlaxoSmithKlineOvarian CancerPhase 3NCT07286266
2030-07-28petrelintideRoche, Zealand PharmaObesityPhase 3NCT07843472
2030-07-29PF-06823859PfizerDermatomyositisPhase 3NCT05895786
2030-07-29Daratumumab, Bortezomib, DexamethasoneJohnson & Johnson, Janssen, Takeda Pharmaceutical CompanyAL AmyloidosisPhase 3NCT06022939
2030-07-30Nivolumab, Relatlimab, pemetrexedBristol-Myers Squibb, Ono Pharmaceutical, Eli LillyNon-Small Cell Lung CancerPhase 3NCT06561386
2030-07-30Semaglutide (Ozempic)Novo NordiskSchizophrenia Disorder, Metabolic Syndrome, Antipsychotic-induced Weight Gain, Cardiovascular Risk, Insulin ResistancePhase 3NCT07770282
2030-07-31Rimegepant (Nurtec ODT)Eisai, PfizerMigrainePhase 3NCT04743141
2030-07-31Goserelin, DocetaxelAstraZeneca, TerSera Therapeutics LLC, SanofiProstate CancerPhase 2/3NCT06282588
2030-07-31baricitinib, N-acetylcysteine, DexamethasoneEli Lilly, Incyte, Apotex Inc.Dengue, Severe Dengue, Mosquito-Borne Diseases, Vector Borne Diseases, Arbovirus Infections, Flavivirus Infections, RNA Virus Infections, Hemorrhagic FeverPhase 3NCT07543458

August 2030

Primary completionDrugDeveloperIndicationPhaseStudy
2030-08 (month only)SeladelparGilead Sciences, Kaken PharmaceuticalPrimary Biliary CholangitisPhase 3NCT06051617
2030-08 (month only)StiripentolBiocodexPrimary Hyperoxaluria Type 1Phase 3NCT06465472
2030-08 (month only)Tirzepatide (Mounjaro), retatrutideEli Lilly, Tanabe Pharma CorporationMetabolic Dysfunction-Associated Steatotic Liver DiseasePhase 3NCT07165028
2030-08 (month only)Pitolisant (Wakix)Bioprojet, Harmony Biosciences, ViatrisPrader-Willi SyndromePhase 3NCT07219485
2030-08 (month only)OlezarsenIonis Pharmaceuticals, Swedish Orphan Biovitrum AB (publ), TheratechnologiesFamilial Chylomicronemia SyndromePhase 3NCT07727538
2030-08-01Denosumab (Prolia)Amgen, Daiichi SankyoCharcot Foot, Diabetes MellitusPhase 3NCT04547348
2030-08-01Axitinib intravitreal implant (OTX-TKI)OCULAR THERAPEUTIX, INCAge-Related Macular Degeneration, Wet Age-Related Macular DegenerationPhase 3NCT07516132
2030-08-01CadonilimabAkesoColon Rectal Cancer Adenocarcinoma, Peritoneal (Metastatic) Cancer, Second-line Treatment, Radiation Therapy, ImmunotherapyPhase 3NCT07815834
2030-08-10Azacitidine, LisaftoclaxBristol-Myers Squibb, Ascentage Pharma Group Inc.Acute Myeloid LeukemiaPhase 3NCT07686965
2030-08-12vedolizumabTakeda Pharmaceutical CompanyUlcerative Colitis, Crohn's DiseasePhase 3NCT06405087
2030-08-30TaletrectinibEisai, Innovent Biologics, Nippon KayakuNon-Small Cell Lung CancerPhase 3NCT07154706
2030-08-31Nab-paclitaxel, GemcitabineBristol-Myers Squibb, Eli LillyPancreatic CancerPhase 3NCT07155629

September 2030

Primary completionDrugDeveloperIndicationPhaseStudy
2030-09 (month only)Brexpiprazole (Rexulti)H. Lundbeck, Otsuka HoldingsBipolar DepressionPhase 3NCT04569448
2030-09 (month only)Brentuximab VedotinPfizer, Seagen, Takeda Pharmaceutical CompanyHodgkin LymphomaPhase 3NCT04685616
2030-09 (month only)Pembrolizumab, NivolumabMerck & Co., Bristol-Myers Squibb, Ono PharmaceuticalMelanomaPhase 3NCT06488482
2030-09 (month only)EmpagliflozinBoehringer Ingelheim, Eli LillyKidney Stone, Nephrolithiasis, Dietary ExposurePhase 3NCT06653738
2030-09 (month only)Venetoclax, AzacitidineAbbVie, Roche, Bristol-Myers SquibbAcute Myeloid LeukemiaPhase 3NCT07082452
2030-09 (month only)Osimertinib, Telisotuzumab AdizutecanAstraZeneca, AbbVieNon-Small Cell Lung CancerPhase 2/3NCT07155187
2030-09 (month only)EverolimusNovartisCowden's Disease, Cowden's Syndrome, Lhermitte-Duclos Disease, Cerebellum Dysplastic Gangliocytoma, Bannayan Zonana Syndrome, Myhre Riley Smith Syndrome, Riley Smith Syndrome, PTEN Hamartoma Tumor Syndrome, Bannayan Riley Ruvalcaba SyndromePhase 2/3NCT07218575
2030-09 (month only)ABBV-706AbbVieSmall Cell Lung CancerPhase 3NCT07365241
2030-09 (month only)RoxadustatAstellas Pharma, AstraZeneca, Kyntra BioMyelodysplastic SyndromesPhase 3NCT07722988
2030-09-01Utidelone, CapecitabineBeijing Biostar Pharmaceuticals, Cheplapharm Arzneimittel GmbHGastric or Gastroesophageal Junction AdenocarcinomaPhase 2/3NCT06841679
2030-09-01Semaglutide (Wegovy)Novo NordiskAortic Stenosis, Heart FailurePhase 3NCT07090343
2030-09-01Semaglutide (Wegovy)Novo NordiskGestational Diabetes Mellitus (GDM), Metabolic SyndromePhase 2/3NCT07797036
2030-09-02Nivolumab, RelatlimabBristol-Myers Squibb, Ono PharmaceuticalUrothelial CarcinomaPhase 2/3NCT05987241
2030-09-02Rituximab, SurovatamigBiogen, Chugai Pharma, RocheLarge B-Cell LymphomaPhase 3NCT07911553
2030-09-04Daratumumab, RamantamigJohnson & JohnsonMultiple MyelomaPhase 3NCT07665450
2030-09-11Datopotamab Deruxtecan, RilvegostomigAstraZeneca, Daiichi Sankyo, COMPUGEN LTDUrothelial CarcinomaPhase 3NCT07720284
2030-09-16zenagamtideNovo NordiskObesityPhase 3NCT07861100
2030-09-18PumitamigBioNTech, Bristol-Myers SquibbNon-Small Cell Lung CancerPhase 3NCT07361497
2030-09-20DeulumateperoneIntra-Cellular Therapies, Johnson & JohnsonGeneralized Anxiety DisorderPhase 3NCT07856420
2030-09-22TrigelSTADA ArzneimittelParkinson's DiseasePhase 3NCT07151378
2030-09-23ZilebesiranAlnylam Pharmaceuticals, RocheHypertensionPhase 3NCT07181109
2030-09-23DepemokimabGlaxoSmithKlineAsthmaPhase 3NCT07456033
2030-09-30Lorlatinib, Sargramostim, DinutuximabPfizer, Partner Therapeutics, Inc., United TherapeuticsNeuroblastomaPhase 3NCT03126916
2030-09-30NivolumabBristol-Myers Squibb, Ono PharmaceuticalMelanomaPhase 3NCT06264180
2030-09-30CabozantinibExelixis, Ipsen, Takeda Pharmaceutical CompanyRefractory Differentiated Thyroid Gland CarcinomaPhase 3NCT06475989
2030-09-30DexamethasoneTick-Borne EncephalitisPhase 3NCT07584525

October 2030

Primary completionDrugDeveloperIndicationPhaseStudy
2030-10 (month only)AbemaciclibEli LillyHR+/HER2- Metastatic Breast Cancer, Breast CancerPhase 3NCT04584853
2030-10 (month only)Delpacibart etedesiranNovartisMyotonic Dystrophy Type 1Phase 3NCT07008469
2030-10 (month only)DarovasertibIDEAYA Biosciences, ServierUveal MelanomaPhase 3NCT07015190
2030-10 (month only)Adebrelimab, Trastuzumab rezetecanJiangsu Hengrui Pharmaceuticals, Glenmark Pharmaceuticals Ltd.Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction AdenocarcinomaPhase 3NCT07118527
2030-10 (month only)CetuximabEli Lilly, Merck KGaAMetastatic Colorectal CancerPhase 3NCT07389265
2030-10 (month only)Lenacapavir (Sunlenca), Tenofovir alafenamide/emtricitabineGilead SciencesHIVPhase 2/3NCT07708727
2030-10-04elecoglipronAstraZeneca, EccogeneChronic Kidney DiseasePhase 3NCT07753993
2030-10-14Lenalidomide, Isatuximab, Methylprednisolone, DexamethasoneBristol-Myers Squibb, Celgene Corporation, SanofiMultiple MyelomaPhase 3NCT04270409
2030-10-15TemozolomideMerck & Co.GlioblastomaPhase 2/3NCT07873996
2030-10-16Efimosfermin alfaGlaxoSmithKlineMASH / NASHPhase 3NCT07704892
2030-10-18Daratumumab, Lenalidomide, ElranatamabJohnson & Johnson, Bristol-Myers Squibb, Celgene CorporationMultiple MyelomaPhase 3NCT05623020
2030-10-21CapecitabineCheplapharm Arzneimittel GmbHPancreatic CancerPhase 3NCT06958328
2030-10-22PacibekitugNovartisMyocardial InfarctionPhase 3NCT07938411
2030-10-24tilrekimigPfizerChronic Obstructive Pulmonary DiseasePhase 2/3NCT07363694
2030-10-30metforminAcute Ischemic StrokePhase 3NCT07899307
2030-10-31phentermine/topiramateVIVUSHealthy VolunteersPhase 3NCT06905626
2030-10-31deucravacitinibBristol-Myers SquibbPsoriatic Arthritis, Psoriasis, Systemic Lupus Erythematosus, Sjögren's DiseasePhase 3NCT07791199
2030-10-31Ivonescimab, Enfortumab VedotinAkeso, Summit Therapeutics, Astellas PharmaMetastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma (UC)Phase 2/3NCT07815665

November 2030

Primary completionDrugDeveloperIndicationPhaseStudy
2030-11 (month only)TemozolomideMerck & Co.GlioblastomaPhase 2/3NCT05685004
2030-11-01Semaglutide (Wegovy)Novo NordiskObesityPhase 3NCT06934655
2030-11-05DostarlimabGlaxoSmithKlineEndometrial CancerPhase 3NCT07860450
2030-11-08PumitamigBioNTech, Bristol-Myers SquibbUntreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaPhase 2/3NCT07221149
2030-11-18Rilvegostomig, pemetrexedAstraZeneca, COMPUGEN LTD, Eli LillyNon-Small Cell Lung CancerPhase 3NCT06627647
2030-11-25MesutoclaxBeijing InnoCare Pharma Tech Co.Chronic Lymphocytic LeukemiaPhase 2/3NCT06378138
2030-11-27ZanzalintinibExelixisRenal Cell CarcinomaPhase 3NCT07489495
2030-11-30QuemliclustatArcus Biosciences, Gilead Sciences, Taiho PharmaceuticalPancreatic Ductal AdenocarcinomaPhase 3NCT06608927
2030-11-30FruquintinibHUTCHMED, Takeda Pharmaceutical CompanyMetastatic Oesogastric AdenocarcinomaPhase 3NCT07270991
2030-11-30Adebrelimab, Gemcitabine, HRS-4642Jiangsu Hengrui Pharmaceuticals, Eli LillyPancreatic CancerPhase 3NCT07900789

December 2030

Primary completionDrugDeveloperIndicationPhaseStudy
2030-12 (month only)mirikizumabEli LillyUlcerative Colitis, Crohn's DiseasePhase 3NCT04844606
2030-12 (month only)metforminAutosomal Dominant Polycystic Kidney DiseasePhase 3NCT04939935
2030-12 (month only)Iparomlimab and tuvonralimabQilu PharmaceuticalColon CancerPhase 3NCT06686576
2030-12 (month only)Ensartinib, Icotinib, RezivertinibBetta Pharmaceuticals Co., Xcovery Holdings, Beta Pharma, Inc.Non-Small Cell Lung CancerPhase 3NCT06955325
2030-12 (month only)FinerenoneBayerHeart FailurePhase 3NCT07270367
2030-12 (month only)Pembrolizumab, Enfortumab VedotinMerck & Co., Astellas Pharma, PfizerBladder CancerPhase 3NCT07346053
2030-12 (month only)HRS-8080Jiangsu Hengrui PharmaceuticalsBreast CancerPhase 3NCT07349069
2030-12 (month only)Izalontamab brengitecanBristol-Myers Squibb, Sichuan Baili PharmaceuticalNon-Small Cell Lung CancerPhase 3NCT07640789
2030-12 (month only)Adebrelimab, Trastuzumab rezetecanJiangsu Hengrui Pharmaceuticals, Glenmark Pharmaceuticals Ltd.Breast CancerPhase 3NCT07679360
2030-12-01EthosuximideEssential Pharma, PfizerIBS - Irritable Bowel SyndromePhase 3NCT04217733
2030-12-01PembrolizumabMerck & Co.Renal Cell CarcinomaPhase 3NCT06146777
2030-12-01vedolizumabTakeda Pharmaceutical CompanyIrAE, Immune-related Adverse Event, Diarrhea, ColitisPhase 2/3NCT06337695
2030-12-01dulaglutideEli LillyAtherosclerotic Cardiovascular DiseasePhase 2/3NCT07282041
2030-12-02Psilocybin (COMP360)COMPASS PathwaysMajor Depressive DisorderPhase 3NCT07226232
2030-12-03remibrutinibNovartisMultiple Sclerosis, Secondary Progressive Multiple SclerosisPhase 3NCT07225504
2030-12-04IptacopanNovartisChronic Kidney Disease, IgA NephropathyPhase 3NCT04557462
2030-12-08PelacarsenIonis Pharmaceuticals, NovartisAtherosclerotic Cardiovascular DiseasePhase 3NCT06875973
2030-12-12Nivolumab, IpilimumabBristol-Myers Squibb, Ono PharmaceuticalNon-Small Cell Lung CancerPhase 2/3NCT04929041
2030-12-16Pembrolizumab, Sacituzumab TirumotecanMerck & Co., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Breast CancerPhase 3NCT06393374
2030-12-20Trastuzumab Deruxtecan, DexamethasoneAstraZeneca, Daiichi SankyoHR+/HER2- Metastatic Breast Cancer, Breast CancerPhase 3NCT07828054
2030-12-22OpamtistomigNanjing Leads Biolabs Co.,LtdAdvanced Extrapulmonary Neuroendocrine CarcinomaPhase 3NCT07720193
2030-12-30EtavopivatNovo NordiskSickle Cell DiseasePhase 3NCT06609226
2030-12-30FinerenoneBayerHeart FailurePhase 3NCT07192952
2030-12-30AbelacimabNovartisAtrial Fibrillation (AF)Phase 3NCT07739888
2030-12-30Nab-paclitaxel, pemetrexedBristol-Myers Squibb, Eli LillyNon-Small Cell Lung CancerPhase 2/3NCT07865910
2030-12-30pemetrexed, ASKC202, LimertinibEli Lilly, Jiangsu Aosaikang Pharmaceutical, Innovent BiologicsNon-Small Cell Lung CancerPhase 3NCT07897188
2030-12-30Serplulimab, FruquintinibAbbott, Accord Healthcare, EisaiRenal Cell CarcinomaPhase 3NCT07904156
2030-12-31Pembrolizumab, Sacituzumab GovitecanMerck & Co., Gilead SciencesUrothelial CarcinomaPhase 3NCT06524544
2030-12-31EsketamineJohnson & JohnsonDepressionPhase 3NCT06713616
2030-12-31Camrelizumab, ApatinibElevar Therapeutics, Inc., Jiangsu Hengrui Pharmaceuticals, Advenchen LaboratoriesHepatocellular CarcinomaPhase 2/3NCT06739317
2030-12-31BevacizumabRocheColorectal CancerPhase 3NCT06791512
2030-12-31BevacizumabRocheColorectal Cancer, Metastatic Colorectal CancerPhase 2/3NCT06958419
2030-12-31NivolumabBristol-Myers Squibb, Ono PharmaceuticalNon-Small Cell Lung CancerPhase 3NCT07050043
2030-12-31PembrolizumabMerck & Co.Cervical CancerPhase 3NCT07061977
2030-12-31HydroxychloroquineAdvanz PharmaSteatohepatitis, NonalcoholicPhase 3NCT07265297
2030-12-31glimepirideSanofiType 2 DiabetesPhase 3NCT07288749
2030-12-31Nab-paclitaxel, SintilimabBristol-Myers Squibb, Innovent BiologicsLocally Advanced Oral Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma (OSCC)Phase 3NCT07371611
2030-12-31Cetuximab, CamrelizumabEli Lilly, Merck KGaA, Elevar Therapeutics, Inc.Head and Neck Squamous Cell CarcinomaPhase 3NCT07432087
2030-12-31CapecitabineCheplapharm Arzneimittel GmbHNasopharyngeal Carcinoma (NPC)Phase 3NCT07590024
2030-12-31Risvutatug rezetecanGlaxoSmithKline, Hansoh Pharmaceutical GroupEsophageal Squamous Cell CarcinomaPhase 3NCT07621601
2030-12-31LenalidomideBristol-Myers Squibb, Celgene CorporationImmunoglobulin G4-Related DiseasePhase 3NCT07719543
2030-12-31Pyrotinib, Fulvestrant, DalpiciclibDr. Reddy's Laboratories, HLB Life Science, Jiangsu Hengrui PharmaceuticalsHER2-Positive Breast Cancer, HR+/HER2- Metastatic Breast Cancer, Breast CancerPhase 3NCT07892274

Source: ClinicalTrials.gov, each study's record, checked daily. Studies that are terminated, withdrawn or completed are left out, as are programmes their developer has stopped. A month-only date is shown as given.